Current articles and info about your health

Saturday, 05th July 2008

   home     about     authors     news     books     xml feed     sitemap     privacy     contact us

There are 6 users online

add to favorites
 make home page


Addiction Issues
 Aging
 Allergies & Sinuses
 Alternative Medicine
 Beauty & Health
 Books & Reading
 Common Illnesses
 Community Service
 Diabetic Health
 Dieting
 Diseases
 Environmental Health
 Exercise and Fitness
 Health Education
 Health Industry
 Health Insurance
 Health Legal Issues
 Health Technology
 Healthcare Services
 Healthy Eating
 Medical Equipment & Products
 Men's Health
 Mental and Emotional Health
 Muscle & Back Pain
 Nutrition and Supplements
 Pediatrics
 Pet Health
 Physical Therapy & Massage
 Prevention Health
 Vision Health
 Weight Management
 Women's Health

Our Newsletter

Sign up for our free
Health-Informant.com Ezine
Get all the latest Health news delivered right to your mailbox.

First Name:

Your Email:



We will never rent, share or sell your name to anyone else... ever! We respect your privacy!
  Other Resources


For other sources of health news, tips, and information, visit our resources page

 

  Submit an Article


Would you like to have your article posted? Click Here
 

 
 

FDA Approved Temodar
Added: 03/16/2005
 Type: Summary
 Viewed: 553 time(s)
 [ Not Rated Yet ]
How would you rate this article:    Bad Good   Go » 
FDA Approved Temodar

March 18, 2005 -- The U.S Food and Drug Administration’s approval of Temodar as a treatment for people newly diagnosed with glioblastoma recognizes the importance of hope. A study published by Roger Stupp, MD, for the European Organization for Research and Treatment of Cancer (EORTC) in last week’s New England Journal of Medicine found that adding Temodar to radiation therapy increased survival rates to 26.5% at two years (from 10.4 % with radiation alone). In an equally compelling report also published in the same journal, studies at the University Hospital of Lausanne indicate the interaction between this drug and a biologic marker called MGMT may provide important information for researchers. These reports signify movement in the treatment of one of the most aggressive brain tumors.

Glioblastoma multiforme is the most common of the primary malignant brain tumors, and is also one of the most difficult tumors to treat effectively. Each year, approximately 20% of all reported brain tumors are glioblastoma. Generally found in people forty through sixty years old, glioblastoma occurs slightly more often in males than females. This tumor tends to be found in the cerebral hemispheres of the brain that control memory, thinking abilities, personality, and movement.

The American Brain Tumor Association offers information about glioblastoma multiforme and Temodar; about other types of brain tumors and their treatments; about standard therapies as well as research treatments; and about support options for brain tumor families seeking help in living with the diagnosis of a brain tumor. Call us at 800-886-2282, or visit our web site at www.abta.org
Physicians available for interviews.

This week’s headlines share our hope… the hope that new knowledge brings to the quality of lives of brain tumor patients around the globe.

Contact:
American Brain Tumor Association
2720 River Rd.
Des Plaines, Il 60618
847-827-9910
www.abta.org
Article Pages:  1  



  Article Comments   Add Comment | View All (0)
    There are currently no comments for this article.


All content © 2008 Webmaster, FDA Approved Temodar :: Health-Informant.com.